Chinese cervical carcinoma patients were recruited at Southwest Hospital (SWH).
Cases with qualified DNA and RNA samples were further included in the sequencing analysis (four sample pairs that failed the molecular quality check were removed).
Additionally, genotyping of 21 SNP loci was performed to ensure the correct pairing of normal and tumor samples, and three sample pairs were removed because of discordant genotypes. A total of 112 sample pairs were used for further analysis after ten sample pairs were removed because of poor data quality.
Normal Cervical tissue cells and CIN specimens
In this study, the tissue cells of normal or CIN were collected from female patients attending a sexually transmitted disease clinic in Shanghai Skin Disease Hospital. The cervical tissue cells were sampled using cervical brushes for each enrolled patient. The
The HPV-DNA testing were analyzed by HC2 method (Qiagen, Hilden, Germany) for For individuals with normal cervical cytology, colposcopy and biopsy are not recommended [1] [2] [3] . However, colposcopy and biopsy were also performed in this study in the following situations: 1) Patients were very anxious about their condition (after high-risk sexual activity) and insisted on accepting further examinations, including biopsy; and 2) Patients agreed to be involved in this study after informed consent was signed. Hence, all patients who were recruited into this study have accepted the examinations of colposcopy and biopsy. The samples of normal or CINs were confirmed by histopathology, which were then used for analysis of HPV integration.
The study was approved by the Ethics Committee of the Shanghai Skin Disease Hospital (No. SKIN2015-010).
DNA extraction and whole-genome or whole-exome sequencing
Genomic DNA was extracted from the blood and tissue samples using TIANamp Blood DNA Kits and TIANamp Genomic DNA Kits (Tiangen Biotech, Beijing, China), respectively, according to the manufacturer's protocols. The amount and integrity of the DNA were assayed using a Qubit® 2. 
Next generation sequencing data processing
Reads generated on the CG platform were processed and assembled using the complete data management solution of Complete Genomics.
Reads generated on the HiSeq 2000 and HiSeq X Ten platforms were processed using the same protocol. First, the raw sequencing reads were filtered as follows to obtain clean data: 1) reads polluted by adapter sequences were removed, as were their mate 7 pair reads; 2) reads with more than 50% of low-quality bases (Q<5) and their mate pair reads were removed; and 3) reads with a high N rate of more than 0.1 and their mate pair reads were removed. The clean reads were then aligned to hg19 (10 CCs and 25
CINs sequenced whole exome on Hiseq X Ten platform were aligned to hg38) using BWA (Burrows-Wheeler Aligner) 6 . Reads with multiple mapping loci in the genome and reads with more than 3 mismatches, with more than 1 gap, or with a gap more than 20 bases long were removed. The duplicated reads derived from PCR amplification were marked using Picard tools (http://broadinstitute.github.io/picard/). Local realignments and base quality recalibrations were performed using GATK 7 .
The bam files generated using the Ion Proton sequencing platform were filtered as follows to obtain high-quality data: 1) reads less than 30 bp or more than 280 bp were removed; 2) reads with a start base not in any primer of the AmpliSeq exome kit primer set were removed; and 3) the first few bases of the reads that overlapped with the primer they were derived from were removed.
The final bam files that were generated were then used for further analysis. The depth of coverage of the target region and the fractions of regions with at least 4-fold, 10-fold, or 20-fold coverage were analyzed. The genotypes of the 21 common SNP sites were checked to ensure that the tissue and matched normal samples were derived from the same patient.
Mutation calling and gene mutational significance analysis
8 Somatic SNV were called using the Strelka 8 (for 10 CCs and 25 CINs sequenced on hiseq X Ten platform) or MuTect algorithm 9 , and further filtrations were performed to obtain a high-confidence somatic SNV. The filter criteria for the SNVs that were called from the WES data generated on the HiSeq 2000 platform were as follows: 1) the reads according to the altered allele in the tumor were no less than five; 2) the fraction of reads according to the altered allele in the tumor was no less than 5%; and 3) the fraction of the reads according to the altered allele in the matched control was less than 3%.
SNVs called from the WGS data generated on the HiSeq X Ten platform were filtered using criteria 2 and 3. The filter criteria for SNVs called from the WES data that were generated on the Ion Proton platform were as follows: 1) the depth of coverage was no less than 20 in the tumor samples and no less than 14 in the control samples; 2) the fraction of the reads supporting the mutation was no more than 2% in the control samples; 3) the fraction of the reads supporting the mutation in the tumor samples was five-fold or more than that in the control samples; 4) the reads supporting the alteration were either no less than 13 and present as a fraction no less than 5% or were no less than 5 and present as a fraction no less than 10%; 5) the mutation did not reside in a highly repeated region or a region with low sequence complexity; and 6) the mutation was supported by both directions of the relevant reads and did not show obvious strand bias (when the supporting reads for a minor allele were only 1, the fraction was no less than 20%, and the fraction was no less than 10% when the supporting reads were more than 1). 9 Somatic small insertions or deletions (indels) were detected using VarScan 2 tools 10 with the default parameters and then were subjected to 3 steps of filtering, as follows:
1) variants that were detected in the matched normal sample (with 3 or more reads supporting an indel in the normal sample at the same location as in the tumor sample or in the 40 bp flanking region) were removed; 2) variants residing near the polyN region were removed; and 3) variants residing near a region with low complexity or short tandem repeat regions were removed. The identified mutations were annotated for information related to the location, function, previous reports, and sequencing data supporting the status of the mutation using a local program. Somatic SNVs and indels for CG-sequenced samples were called and annotated using CG data management solutions. A MutsigCV tool 11 was used to find significantly mutated genes. Somatic
SNVs and indels located in exons and spliced regions were input into MutsigCV and analyzed using the default parameters. Genes with a FDR no more than 0.1 were considered to be significantly mutated.
Copy number variation analysis
For the CG sequenced samples, CNAs were called using CG data management solutions, and for the other samples, CNAs were called using CLImAT software 12 with the input data processed using local scripts. For HiSeq X Ten-sequenced samples, the whole genome was divided into 400 bp bins that contained a SNP site and its flanking sequence. A total of 12,183,239 bins were generated for each sample using SNPs chosen from the dbSNP database (dbSNP 137) with a MAF of no less than 0.05 and no clustering in genomic regions. The read depth was then extracted for each bin from the 10 bam files, and the copy ratios were calculated by dividing the depth of each bin of cancer tissues by the depth of the same bin of matched controls. Then, we performed GC normalization before performing centralization using the copy ratio mode. The correlation between the copy ratio and the GC content was normalized, and the noise caused by GC bias was reduced. The B allele frequency was calculated and integrated with the final copy ratio as the input data for CLImAT. CNAs were called using this (the sample subjected to WES on both the HiSeq and the proton platforms), CC-H014, CC-H017 and CC-H021, were subjected to low-depth whole-genome sequencing.
Correlation analyses between the CNAs generated from the WGS and WES data were performed to evaluate whether the somatic CNAs called using the WES data had a detecting power that was similar to that of the WGS data.
We analyzed multiploid genomes using a local script according to the results of CLImAT and the following criteria: 1) if >50% of the 'normal regions' showed LOH, we considered the sample to be multiploid; and 2) if >10 M deleted regions showed balanced allele-frequency, we considered the sample to be multiploid. GISTIC2.0 tools 13 were used to identify the frequently altered broad and focal CNAs (q≤0.25), and an in-house designed algorithm was used to find additional CNA peaks. Besides, an in-11 house design algorithm was used to identify CNA peaks as a supplement, which contain four steps. 1, For each gene, the number of samples had an amplification or deletion on which was counted and then a p value based on one tail test of Poisson distribution was calculated both for amplification and deletion. 2, For each chromosome arm, we searched out local maximum value for amplification numbers and deletion numbers. A gene or several contiguous genes which has local maximum value was considered as a candidate peak if the p value of its amplification number/deletion number is no more than 0.01. 3, We discard a candidate peak if the following conditions were satisfied. (1),
There is another candidate peak within ten megabase from this candidate peak and the amplification/deletion numbers of it was higher than that of this candidate peak (2), The average amplification/deletion numbers of genes between the two candidate peaks was higher than that of this candidate peak. 4, To get the peak regions for peaks passed the third step, we expand the coordinates on both sides until (1) p value of the gene on the border >0.01. (2) The difference of amplification/deletion numbers between the gene on the border and the peak was no more than five.
Genomic rearrangement and gene fusion analysis
We used the CREST algorithm 14 to detect structural variation in the WGS data describing the matched tumor and normal tissues. The CREST algorithm extracted softclipped reads to detect structural variation in sites at a base pair resolution. The software used bam files, which were generated by BWA alignment. We performed CREST using the default parameters. The pipeline included three steps: 1) we extracted soft-clipped breakpoints; 2) we removed germline variation by running the Perl script countdiff.pl; 12 and 3) we detected structural variations. The detection procedure was processed as follows: we assembled the soft-clipped reads, mapped the sequences, reassembled the other side of the putative breakpoint using BLAT (BLAST-like Sequence Alignment Tool), and, finally, if both sides showed high alignment similarity, they were reported as a putative structural variation event.
Chromosomes with inferred chromthripsis were detected based on the criteria proposed by Korbel and Campbell 15 . Briefly, evidence of chromothripsis was considered when breakpoints were highly clustered in a chromosome (exponential distribution, p<0.001), copy numbers oscillations≥6, or when loss of heterogeneity, random DNA joins, or randomly ordered DNA fragments were observed.
To identify fusion genes, we used the TopHat-Fusion algorithm to detect the mRNA expression of fusion genes 16 . Putative fusion genes were filtered out by at least two span reads, at least two pair end reads, and no less than five total supporting reads.
HPV integration analysis
HPV sequences from human genomic DNA were captured and sequenced to an ultrahigh coverage, yielding approximately one GB of data for each sample. On average, 94.8% of the raw data (total of 1.6 GB) after the removal of the low-quality data were used for HPV integration breakpoint analysis.
Five steps were performed to analyze HPV integration, namely, reads identification, location and orientation definition, clustering and filtering of results, annotation, and integrant (integrated HPV fragments) prediction. 13 To identify reads that supported HPV integration, reads were aligned to the HPV genome and, subsequently, to the human genome using BWA. HPV reference genomes were obtained from NCBI (ftp://ftp.ncbi.nih.gov/genomes/). A single-end read of at least 50 bp mapped to the HPV genome was kept, as well as its matching pair reads, and these reads were then mapped to the human genome. Then, reads of at least 30 bp that matched and their matching pair reads were kept. Chimeric reads (when one part of a read mapped to the HPV genome and the other part mapped to the human genome) and discordant read-pairs (when one read mapped to the HPV genome and the matched read mapped to the human genome) were identified, and HPV integrations were analyzed using these reads. HPV integration has previously been shown to cause variation around the integration site 17 . Therefore, 10-bp mismatches or gaps were allowed for discordant read-pairs, and a 15-bp overlap was allowed for chimeric reads.
Exact locations in the human and HPV genomes were identified for chimeric readsupported integrations, and for discordant read-pairs, the positions nearest to the potential junction were reported. In addition, integration orientations were defined according to which end of a read mapped to which strand of the HPV and human genomes. The orientation of a chimeric read at the human end was considered (1) Integration breakpoint clustering and filtering were performed as the third step.
Chimeric reads that mapped as nearly identical (the predicted breakpoints were located within ±70 bp in the human genome and ±70 bp in the HPV genome and had the same orientation) were considered to be one integration event, with the leftmost integration site being the output. Then, integrations supported by discordant read-pairs were clustered to the adjacent integrations (located within 500 bp and having the same orientation) supported by chimeric reads, and locations of chimeric read-supported integrations were reported. Then, discordant read-pair-supported integrations that could not cluster to a chimeric read-supported integration were clustered with each other at locations within 600 bp in the human genome and 500 bp in the HPV genome and with the same orientation. The nearest positions to the predicated junctions were reported.
After clustering, the results were filtered, with removal of integrations supported by only one read.
Annotation of high-confidence integrations was performed using ANNOVAR 18 and a local algorithm. The genomic location of the integration was annotated, including the genomic position and cytoband, and disrupted genes in both the human and HPV genomes (upstream and downstream genes were reported for the integrations located in intergenic regions).
To check the sizes of the viral integrants within the human genome, we identified the most possible integration partners for each integration junction. Two closet breakpoints 15 located in the same chromosome and same HPV strains genome, with complementary orientations, were identified as integration partners. Size of HPV integrants were calculated using these partners.
Validation for gene mutation and HPV integration
To validate the somatic SNVs identified in our cohort, mass spectrometry (MS)-based genotyping was used. Multiplex genotyping primers and extension probes were designed using Agena Bioscience's online design tools (https://mysequenom.com/Logon.aspx?ReturnUrl=%2fTools), and genotyping was performed on a MassArray® System (Agena Bioscience, Hamburg, Germany). HPV integration junctions and integrants were also validated using PCR and Sanger sequencing. For integration junctions, primers pairs were designed with one primer mapped to the human genome, the other primer mapped to the HPV genome, and with the junction located within the predicted amplicon. Successfully amplified samples were subjected to Sanger sequencing to confirm the integration breakpoints in both the HPV and the human genomes. For integrants, long PCR was used with both primers mapped to the human genome and with the full length of the integrated HPV fragment and the surrounding human sequence on both ends included within the predicated 16 amplicon. Sanger sequencing was performed on both ends of the amplicon to validate both junctions of the integrant.
RNAi-mediated gene silencing and cell viability analyses
Three siRNAs directed against 47 target genes were designed using the Whitehead Institute Web Server (http://jura.wi.mit.edu/bioc/siRNAext/) and then chemically All experiments were independently repeated at least three times.
